BPC-157: doses reported in published research

Sources checked 2026-10-07 · 5 cited studies (2 human, 3 animal, 0 cell culture) · 3 registered trials

BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV). Most published dose data come from rodent studies; human reports are limited to small uncontrolled studies and registered trials.

Human data: are limited to two small uncontrolled reports from one private clinic (2 and 12 participants) and registered trials without published results.

Studies in people (2)

Human 2 adults (58 and 68 years), open-label pilot at a private clinic

Dose as reported: 10 mg on day 1, then 20 mg on day 2
Route: Intravenous infusion (in 250 cc normal saline over 1 hour)
Frequency / duration: Two infusions on consecutive days

Source wording: On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour.

Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PubMed PMID 40131143 ↗

Human 12 women (39-76 years) with interstitial cystitis, uncontrolled pilot at a private clinic

Dose as reported: 10 mg total
Route: Into the bladder wall around the inflamed area, during cystoscopy
Frequency / duration: Single procedure

Source wording: The women underwent cystoscopy and were treated with injections of the peptide BPC-157 (total of 10 mg) around the area of inflammation of the bladder during a single procedure.

Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PubMed PMID 39325560 ↗

Animal studies (3)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal Rats (transected Achilles tendon)

Dose as reported: 10 µg/kg, 10 ng/kg or 10 pg/kg (separate groups)
Route: Intraperitoneal
Frequency / duration: Once daily; first 30 min after surgery, last 24 h before analysis

Source wording: Agents (/kg b.w., i.p., once time daily) (BPC 157 (dissolved in saline, with no carrier addition) (10 microg, 10 ng or 10 pg) or saline (5.0 ml)), were firstly applied at 30 min after surgery, the last application at 24 h before autopsy.

Staresinic M, Sebecic B, Patrlj L et al.. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003. PubMed PMID 14554208 ↗

Animal Rats (Achilles tendon detached from bone)

Dose as reported: 10 µg/kg, 10 ng/kg or 10 pg/kg (separate groups)
Route: Intraperitoneal
Frequency / duration: Once daily; first 30 min after surgery, last 24 h before analysis (assessed up to day 21)

Source wording: agents [BPC 157 (10 microg, 10 ng, 10 pg), 6alpha-methylprednisolone (1 mg), 0.9% NaCl (5 mL)] were given alone or in combination [/kg body weight (b.w.) intraperitoneally, once time daily, first 30-min after surgery, last 24 h before analysis] Tested at days 1, 4, 7, 10, 14, and 21 after Achilles detachment

Krivic A, Anic T, Seiwerth S et al.. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006. PubMed PMID 16583442 ↗

Animal Rats (transected quadriceps muscle)

Dose as reported: 10 µg/kg, 10 ng/kg or 10 pg/kg (separate groups)
Route: Intraperitoneal
Frequency / duration: Once daily (observation period up to 72 days)

Source wording: BPC 157 (10 microg, 10 ng, 10 pg/kg) is given intraperitoneally, once daily; 72-day period

Staresinic M, Petrovic I, Novinscak T et al.. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006. PubMed PMID 16609979 ↗

Registered trials (3)

From ClinicalTrials.gov records. Registry entries describe planned designs; they are not published results.

Registered trial (no published results) Healthy volunteers, phase 1 (PCO-02, oral tablet of BPC-157 under the name Bepecin); status unknown, no results posted

Dose as reported: Tablets containing 1 mg; single doses of 1, 3 or 6 tablets (phase 1a); 3 tablets every 8 hours for 2 weeks (phase 1b)
Route: Oral
Frequency / duration: Single dose, or every 8 hours for 2 weeks

Source wording: Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks

PCO-02 - Safety and Pharmacokinetics Trial. ClinicalTrials.gov registry record. NCT02637284 ↗

Registered trial (no published results) Adults with acute hamstring strain, phase 2, recruiting; no results

Dose as reported: Not stated in the registry record
Route: Subcutaneous
Frequency / duration: Once daily for 14 days

Source wording: Schedule: once daily for 14 days.

BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov registry record. NCT07437547 ↗

Registered trial (no published results) Adults after rotator cuff repair, phase 1, not yet recruiting; no results

Dose as reported: Not stated in the registry record
Route: Subcutaneous
Frequency / duration: Once daily for 90 days

Source wording: once daily for 90 days following arthroscopic rotator cuff repair

Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. ClinicalTrials.gov registry record. NCT07803250 ↗

Half-life

Animal Elimination half-life of unchanged BPC-157 under 30 minutes after intravenous or intramuscular dosing in rats and beagle dogs. Source wording: the elimination half-life (t1/2) of prototype BPC157 was less than 30 min
He L, Feng D, Guo H et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PubMed PMID 36588717 ↗

A 2021 retrospective chart review of intra-articular knee use (PMID 34324435) does not report the amount given in its abstract, so it is not tabulated here.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.